HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael Reusch Selected Research

Prolyl-Hydroxylase Inhibitors

4/2022Two Phase 3 Studies on Ophthalmologic Effects of Roxadustat Versus Darbepoetin.
10/2021Roxadustat for the Maintenance Treatment of Anemia in Patients with End-Stage Kidney Disease on Stable Dialysis: A European Phase 3, Randomized, Open-Label, Active-Controlled Study (PYRENEES).
10/2021Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients.
7/2021Phase 3 Study of Roxadustat to Treat Anemia in Non-Dialysis-Dependant CKD.
1/2021Roxadustat for the treatment of anemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, double-blind, placebo-controlled study (ALPS).
1/2021Roxadustat for the treatment of anaemia in chronic kidney disease patients not on dialysis: a Phase 3, randomized, open-label, active-controlled study (DOLOMITES).
12/2020Oral roxadustat three times weekly in ESA-naïve and ESA-converted patients with anemia of chronic kidney disease on hemodialysis: Results from two phase 3 studies.
4/2020Intermittent Oral Dosing of Roxadustat in Peritoneal Dialysis Chronic Kidney Disease Patients with Anemia: A Randomized, Phase 3, Multicenter, Open-Label Study.
1/2020Phase 3, Randomized, Double-Blind, Active-Comparator (Darbepoetin Alfa) Study of Oral Roxadustat in CKD Patients with Anemia on Hemodialysis in Japan.
1/2020A Phase 3, Multicenter, Randomized, Two-Arm, Open-Label Study of Intermittent Oral Dosing of Roxadustat for the Treatment of Anemia in Japanese Erythropoiesis-Stimulating Agent-Naïve Chronic Kidney Disease Patients Not on Dialysis.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael Reusch Research Topics

Disease

13Chronic Renal Insufficiency
04/2022 - 01/2019
11Anemia
04/2022 - 01/2019
11Hypoxia (Hypoxemia)
04/2022 - 01/2019
4Neoplasms (Cancer)
02/2021 - 09/2016
2Retinal Hemorrhage
04/2022 - 01/2020
2Carcinoma (Carcinomatosis)
02/2021 - 03/2019
2Psoriasis (Pustulosis Palmaris et Plantaris)
08/2014 - 01/2014
1Chronic Kidney Failure (Chronic Renal Failure)
10/2021
1Stroke (Strokes)
10/2021
1Myocardial Infarction
10/2021
1Unstable Angina
10/2021
1Heart Failure
10/2021
1Hypertension (High Blood Pressure)
01/2021
1Adenoma (Adenomas)
03/2019
1Cardiovascular Diseases (Cardiovascular Disease)
01/2019
1Melanoma (Melanoma, Malignant)
09/2016
1Hypersensitivity (Allergy)
06/2013
1Seasonal Allergic Rhinitis (Hay Fever)
06/2013

Drug/Important Bio-Agent (IBA)

13roxadustatIBA
04/2022 - 01/2019
11Prolyl-Hydroxylase InhibitorsIBA
04/2022 - 01/2019
3HematinicsIBA
12/2020 - 01/2020
2Hemoglobins (Hemoglobin)IBA
10/2021 - 10/2021
2Darbepoetin alfa (Aranesp)FDA Link
10/2021 - 01/2020
2Androgen Receptors (Androgen Receptor)IBA
02/2021 - 03/2019
2Keratins (Keratin)IBA
02/2021 - 03/2019
2Perilipin-2IBA
02/2021 - 03/2019
2IronIBA
01/2021 - 01/2020
1omega-Chloroacetophenone (Mace)IBA
10/2021
1AntibodiesIBA
02/2021
1Proteins (Proteins, Gene)FDA Link
02/2021
1LDL Lipoproteins (beta Lipoproteins)IBA
01/2021
1oxidized low density lipoproteinIBA
01/2021
1Mucin-1 (CA 15-3 Antigen)IBA
03/2019
1Indicators and Reagents (Reagents)IBA
01/2017
1Midazolam (Versed)FDA LinkGeneric
09/2016
1Cholecalciferol (Vitamin D3)FDA Link
08/2014
1VitaminsIBA
08/2014
1Adrenal Cortex Hormones (Corticosteroids)IBA
08/2014
1calcipotriene (calcipotriol)FDA LinkGeneric
08/2014
1Biological ProductsIBA
01/2014
1Anti-Allergic Agents (Antiallergic Agents)IBA
06/2013

Therapy/Procedure

3Renal Dialysis (Hemodialysis)
10/2021 - 01/2020
2Therapeutics
08/2014 - 06/2013
1Peritoneal Dialysis
04/2020
1Self Medication
06/2013